MAQUET Cardiovascular today announced the launch of its VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting (EVH) System, which utilizes next-generation HEMOPRO cut-and-seal technology to reduce thermal spread and to achieve optimal conduit quality for coronary artery bypass graft (CABG) surgery patients. The minimally invasive VASOVIEW HEMOPRO 2 system is an example of MAQUET Cardiovascular's commitment to EVH, and technologies that promote the highest level of conduit quality.
"I expect VASOVIEW HEMOPRO 2 to lead the way in redefining best practices for EVH," said Valavanur Subramanian, M.D., Chairman, Department of Cardiothoracic Surgery, at Lenox Hill Hospital in New York. "Surgeons across the United States will welcome this innovative EVH product in their practices as it offers important new features such as zero thermal spread (when used in accordance with the Instructions for Use) that can help improve cardiac surgery outcomes."
After recently trying this new product with a number of CABG patients, Keith Causey, Chief Physician Assistant from Emory Healthcare, agrees. "My objective as a harvester is to provide the best conduit quality possible for long-term graft patency and clinical success. The improvements to this HEMOPRO 2 system made my vessel harvesting experience better and I am thoroughly convinced it represents a new gold standard in both saphenous vein and radial artery harvesting. I appreciate the spot cautery feature and am especially impressed by the superior sealing capability. This new EVH system is a victory for patients".
The newly designed HEMOPRO 2 Jaws feature a unique insulated area, providing the main conduit maximum protection during side branch dissection. The HEMOPRO 2 Jaws also feature an enhanced edge for spot cautery to provide a clearer working tunnel and extended cutting capability to allow cutting even from within the innermost corner of the tool. These design changes improve the robustness of the EVH procedure and are easy for users to learn.
The VASOVIEW HEMOPRO 2 System can be used in conjunction with the new VASOSHIELD Pressure Controlling Syringe, also recently introduced by MAQUET Cardiovascular. For a harvested artery or vein, the VASOSHIELD Pressure Controlling Syringe helps prevent overdistension during vessel preparation steps, thus protecting endothelial integrity. Uncontrolled pressure with a standard syringe may cause overdistension of the vessel prior to surgery, which can injure the endothelial lining of the vessel, potentially affecting long term patency results.
"No other company offers this same powerful combination of new tools to help preserve conduit quality for EVH and cardiac surgery patients. We continue to lead the way by delivering technology advancements that are simple to use yet can improve clinical outcomes and enhance quality of life," said Christian Keller, President and CEO, MAQUET Cardiovascular.
Online group programs aid weight loss but face hurdles